Entrectinib
Rozlytrek (entrectinib) is a small molecule pharmaceutical. Entrectinib was first approved as Rozlytrek on 2019-08-15. It is used to treat non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat neoplasms and non-small-cell lung carcinoma. Rozlytrek's patents are valid until 2038-07-18 (FDA).
Trade Name | Rozlytrek |
---|---|
Common Name | Entrectinib |
Indication | neoplasms, non-small-cell lung carcinoma |
Drug Class | Tyrosine kinase inhibitors: tropomyosin receptor kinase (TRK) inhibitors |